NeoADAURA: NCT04351555: Phase 3: Osimertinib VS Osimertinib + Chemo VS Chemo Alone - Neoadjuvant Therapy - EGFRm Positive Resectable Non-Small Cell Lung Cancer
First Posted 2020-04-17 Trial status Active, not recruiting Sponsor AstraZeneca Abstract Presentation Peer-reviewed journal publication Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer J Clin Oncol Sep 2025 PUBMED JCO NCCN FDA NeoADAURA: NCT04351555: Phase 3: Osimertinib VS Osimertinib + Chemo VS Chemo Alone - Neoadjuvant Therapy - EGFRm Positive Resectable Non-Small Cell Lung Cancer (A Study of Osimertinib With or Without Chemotherapy Versus Che
Dec 15, 2025